Td Asset Management Inc Zymeworks Inc. Transaction History

Td Asset Management Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 10, 2022	SELL	$6.0 - $16.98 $253,572 - $717,608	-42,262 Closed	0 $0
Q3 2021 Nov 09, 2021	BUY	$27.35 - $37.28 $270,765 - $369,072	9,900 Added 30.59%	42,262 $1.23 Million
Q1 2021 May 14, 2021	BUY	$29.83 - $56.81 $162,633 - $309,728	5,452 Added 20.26%	32,362 $1.02 Million
Q4 2020 Feb 16, 2021	SELL	$39.12 - $54.99 $152,568 - $214,461	-3,900 Reduced 12.66%	26,910 $1.27 Million
Q2 2020 Aug 13, 2020	BUY	$33.67 - $40.0 $13,468 - $16,000	400 Added 1.32%	30,810 $1.11 Million
Q1 2020 May 15, 2020	SELL	$24.28 - $49.8 $85,101 - $174,549	-3,505 Reduced 10.33%	30,410 $1.08 Million
Q4 2019 Feb 11, 2020	BUY	$24.84 - $45.46 $81,972 - $150,018	3,300 Added 10.78%	33,915 $1.54 Million
Q3 2019 Nov 07, 2019	BUY	$22.78 - $29.08 $430,542 - $549,612	18,900 Added 161.33%	30,615 $759,000
Q2 2019 Aug 01, 2019	BUY	$15.0 - $22.49 $175,725 - $263,470	11,715 New	11,715 $258,000

296K

Ticker ZYME
Exchange NYSE
Sector Healthcare
Industry Biotechnology
Shares Outstandng 61,694,400
Market Cap $766M
Description
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas...

Get notified when there are updates to the investment portfolio of Td Asset Management Inc, based on Form 13F filings with the SEC.

Stay updated on Td Asset Management Inc with notifications on news.